Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Deferiprone in Treatment-Naïve HIV-Positive Subjects
NCT02456558Phase 1Completed
- Sponsor
- ApoPharma Inc.
- Start
- Jun 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deferiprone in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ApoPharma Inc. Primary endpoints: Change from baseline in HIV viral load, Change from baseline in CD4+ T-cell count and 3 more. Started Jun 2015; status: completed.
02
Drugs
deferiprone
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02456558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02456558.